×

Do you want to link to this External Site and leave Amgen.com.sg?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen website and leave Amgen.com.sg?

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Singapore takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Singapore Affiliate

Amgen opened a Singapore affiliate in December 2015 to market its innovative medicines for patients suffering from serious illnesses. This will further strengthen Amgen’s capabilities to address the region’s growing healthcare needs and provide treatments for patients in Singapore. 

Amgen’s initial priorities in Singapore will include:

  • Working with healthcare providers and payers to ensure the patients who can benefit from Amgen’s approved medicines can access them;
  • Advancing its clinical pipeline, which includes treatments for bone disease, cardiovascular, hematology / oncology, nephrology, inflammation, neuroscience and biosimilar medicines;
  • Being an active member in the local biotechnology industry to encourage mutual growth while contributing to the ongoing creation of an environment where the industry can thrive.

Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. Products currently approved in Singapore include: Prolia® (denosumab), XGEVA® (denosumab), Vectibix® (panitumumab), NEUPOGEN® (filgrastim) and Neulastim® (pegfilgrastim).

By working closely with the Health Sciences Authority on multiple drug registrations, Amgen is working towards ensuring more of its vital medicines are made available to patients in Singapore as soon as possible.